Skip to content

Investigation of Proteomic Heterogeneity of Proteins, Metabolomics, and Proteomic Heterogeneity of Extracellular Vesicles Derived From Different Human Blood Circulatory Regions

Investigation of Proteomic Heterogeneity of Proteins, Metabolomics, and Proteomic Heterogeneity of Extracellular Vesicles Derived From Different Human Blood Circulatory Regions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119293
Enrollment
Unknown
Registered
2026-02-25
Start date
2025-07-29
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid hemorrhage

Interventions

Unruptured intracranial aneurysm group:None

Sponsors

First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 60 years, with no restriction on gender; 2. Definite diagnosis of intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have radiological evidence of hemorrhage on head CT, and the interval between hemorrhage onset and blood sample collection must not exceed 3 days; 4. Scheduled to undergo neurointerventional treatment of intracranial aneurysm under general anesthesia; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pre-onset modified Rankin Scale (mRS) score >= 2 for hemorrhagic patients, or preoperative mRS score >= 2 for non-hemorrhagic patients; 2. Presence of other neurological disorders such as Parkinson’s disease, Alzheimer’s disease, cerebral infarction, brain tumors, or epilepsy; 3. Presence of other systemic diseases such as diabetes, coronary heart disease, cancer, infections, hematological disorders, or severe metabolic diseases that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT > 3 × upper limit of normal; creatinine > 225 µmol/L); 5. Unable to tolerate anesthesia or anticoagulant therapy, or with coagulation disorders; 6. History of severe reactions to contrast agents; 7. Pregnancy; 8. Participation in other clinical trials with follow-up not yet completed.

Design outcomes

Primary

MeasureTime frame
Serum proteomics;Serum metabolomics;Extracellular vesicles proteomics;

Countries

China

Contacts

Public ContactHonglei Wang

First Hospital of Jilin University

wanghongl@jlu.edu.cn+86 187 4305 9601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026